CSF3 and Renal insufficiency: These include (1) indications for the start of treatment (presymptomatic vs. symptomatic); (2) the optimal dose and criteria for dose adaptions; (3) when to taper/stop G‐CSF; (4) optimal monitoring; (5) risk of side effects; (6) possible long‐term effects including improvement of renal function/prevention of renal insufficiency; and (7) individual pharmacogenetic and pharmacokinetic factors that influence the treatment effect.